BMO Capital analyst Ian Somaiya initiated coverage with a Buy rating on Ra Pharmaceuticals (NASDAQ: RARX) today and set a price target of $20. The company’s shares closed yesterday at $10.94.
According to TipRanks.com, Somaiya is ranked #433 out of 4840 analysts.
Currently, the analyst consensus on Ra Pharmaceuticals is a Moderate Buy with an average price target of $18.
See today’s analyst top recommended stocks >>
Based on Ra Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $16.5 million. In comparison, last year the company had a GAAP net loss of $12.66 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of peptide-based drugs for a variety of therapeutic uses. The firm’s lead product, RA101495 SC, which is an injection into the tissue under the skin, for the treatment of paroxysmal nocturnal hemoglobinuria.